Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Rivastigmine, an acetylcholinesterase inhibitor which has been approved by FDA & HSA, is
authorized for use in the treatment of mild to moderate dementia of the Alzheimer's type.
In this trial, the investigators will be studying the effectiveness of Rivastigmine in
subjects with AD and cerebrovascular disease.